COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
15/02/2024
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal [...]
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
15/02/2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
15/02/2024
Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard kits // QIAGEN’s Sample technologies R&D lab in Germany [...]
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
15/02/2024
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 WALTHAM, Mass., Feb. 15 [...]
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
15/02/2024
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE [...]
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
15/02/2024
MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it [...]
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
15/02/2024
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in [...]
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
15/02/2024
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a [...]
Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
15/02/2024
SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular [...]
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
15/02/2024
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of [...]
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
15/02/2024
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
15/02/2024
DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies [...]
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
15/02/2024
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to [...]
Galapagos presents at EBMT-EHA annual meeting 2024
15/02/2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV [...]
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15/02/2024
Received 459 new patient start forms (PSFs) for FILSPARI ® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to [...]
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15/02/2024
NX-5948 received Fast Track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new development candidate, NX- [...]
Beacon Behavioral Partners Celebrates Expansion Across the Southeast United States
15/02/2024
The network of physician-driven psychiatric practices experienced significant annual growth, reflecting the success of its expansion strategy BATON ROUGE, La., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Beacon Behavioral [...]
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
15/02/2024
DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs [...]
Mithra sells shares in Mayne Pharma
15/02/2024
Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 million As the Mayne Pharma shares were pledged to the secured lenders of Mithra, the cash proceeds will be held [...]

Pages